Médecine

Paramédical

Autres domaines


S'abonner

Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies - 12/12/19

Doi : 10.1016/j.jbspin.2019.11.003 
Tahmina Nasrin Poly a, b, e, Md. Mohaimenul Islam a, b, e, Hsuan-Chia Yang a, b, e, Yu-Chuan (Jack) Li a, b, c, d, e,
a Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan 
b International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan 
c Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan 
d TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan 
e Research Center of Big Data and Meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 

Corresponding author. Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan.Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University250 Wu-Hsing St.Taipei 110Taiwan
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Thursday 12 December 2019
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Highlights

Hip fracture is one of the leading causes of disability, cost, morbidity and mortality.
The primary objective of this study was to evaluate the magnitude of hip fracture risk with BDZs.
In BDZs users, compared with non-users, the RR for hip fracture was 1.34 (95%CI: 1.26–1.44).
Physicians should be aware of the unwanted consequence of BDZs when they will prescribe BDZs for their patients, especially elderly patients because hip fractures are highly prevalent in the elderly population.

Le texte complet de cet article est disponible en PDF.

Abstract

Objective

Hip fracture is one of the leading causes of disability, cost, morbidity, and mortality. Several studies reported that benzodiazepines (BDZs) have been associated with an increased risk of hip fracture in older individuals. The aim of this study was to evaluate the magnitude of hip fracture risk with BDZs.

Methods

A systematic literature search on EMBASE, PubMed, Google Scholar, Scopus was performed between January 1, 1980, and March 31, 2019. The search strategy was based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, and an observational study design was mandatory for articles inclusion. Data were extracted by two authors independently and a random effect model was used to evaluate effect size. The random-effects model (DerSimonian-Laird) was utilized to obtain the overall risk ratio (RR) and its 95% CI for all studies. The Newcastle Ottawa Scale (NOS) was also used to assess the quality of each study.

Results

Of 2315 studies screened, 33 (20 cohorts and 13 case-control) with 169,660 hip fracture cases were included in our analysis. In BDZs users, compared with non-users, the RR for hip fracture was 1.34 (95%CI: 1.26–1.44). The RR for long- and short-short acting BDZs and hip fracture risk were 1.31 (95%CI: 1.18–1.45, P<0.0001), and 1.15 (95%CI: 1.08–1.22, P<0.0001), respectively. When stratified by type of users, the current and recent users of BDZs had higher risk of hip fracture (RR: 1.83, 95% CI: 1.46–2.28, P<0.0001 and RR: 1.61, 95% 1.30–1.99, P<0.0001) whereas there was no increased risk of hip fracture in past BDZs users (RR: 1.18, 95%CI: 1.07–1.29, P<0.0001).

Conclusion

Our meta-analysis showed an increased risk of hip fracture in patients with BDZs compared with non-users. Physicians should be aware of the unwanted consequence of BDZs when they will prescribe BDZs for their patients, especially elderly patients because hip fractures are highly prevalent in the elderly population.

Le texte complet de cet article est disponible en PDF.

Keywords : Hip fracture, Fracture, Osteoporosis, Benzodiazepine, Anxiety, Depression


Plan


© 2019  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.